Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer

Cancer Research

Volumn 62, Issue 7, 2002, Pages 2019-2023

  Hasumi, Yoko ^a,c   Mizukami, Hiroaki ^a   Urabe, Masashi ^a   Kohno, Takahiro ^a   Takeuchi, Koichi ^b   Kume, Akihiro ^a   Momoeda, Mikio ^c   Yoshikawa, Hiroyuki ^c   Tsuruo, Takashi ^d   Shibuya, Masabumi ^e   Taketani, Yuji ^c   Ozawa, Keiya ^a  

^a Jichi Medical University   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d Institute of Molecular and Cellular Biosciences   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; PROTEIN; PROTEIN NEO; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES FLUID; ASCITES TUMOR; BLOOD VESSEL PERMEABILITY; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ASCITES; CELL DIVISION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SOLUBILITY; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036531821     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ovarian cancer: Screening, treatment, and follow up
2. Cancer statistics, 1996
3. Evaluation of selected prognostic factors in ovarian cancer
4. What is the evidence that tumors are angiogenesis dependent?
5. Kinetics of angiogenesis in small vessels related to mouse parietal peritoneum
6. Prevention of carcinomatosis and bloody malignant ascites in the rat by an inhibitor of angiogenesis
7. Fluid accumulation during initial stages of tumor growth
8. Genesis of ascites in ovarian cancer
9. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
10. Malignant ascites. Clinical and experimental observations
11. Mechanisms of malignant ascites production
12. Pharmacologically active substances in malignant ascites fluid
13. Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation
14. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer
15. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue
16. Kinin-generating cascade in advanced cancer patients and in vitro study
17. Human malignant ascites and histamine-induced protein leakage from the normal microcirculation
18. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice
19. Epidermal growth factor and transforming growth factor α induce ascitic fluid in mice
20. Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining
21. Role of VEGF-flt receptor system in normal and tumor angiogenesis
22. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
23. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
24. Identification of a natural soluble form of the vascular endothelial growth factor receptor. FLT-1, and its heterodimerization with KDR
25. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
26. Establishment of a human ovarian clear cell carcinoma cell line (RMG-1) and its single cell cloning-with special reference to the stem cell of the tumor
27. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria
28. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors
29. Genomic organization of the flt-I gene encoding for vascular endothelial growth factor (VEGF) receptor-I suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors
30. Adeno-associated virus vectors can be efficiently produced without helper virus
31. Yamada its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice
32. The effect of long-term vasodilatation on capillary growth and performance in rabbit heart and skeletal muscle
33. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody
34. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization
35. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor
36. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
37. Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes
38. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice
39. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival
40. Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: Evidence for a high transduction efficiency into primary epithelial cancer cells
41. Recombinant adeno-associated virus for muscle directed gene therapy
42. Adeno-associated virus vectors preferentially transduce cells in S phase
43. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector